Related Experiment Video
Updated: Mar 15, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
Soft tissue sarcoma in the dog - part 1: a current review.
1Veterinary Teaching Hospital, Institute for Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North 4442, New Zealand. J.P.Bray@massey.ac.nz.
The Journal of Small Animal Practice
|September 15, 2016
Summary
Management of canine soft tissue sarcomas is complex. This review updates current understanding, highlighting uncertainties in predicting surgical margins and the need for tailored treatment based on tumor aggressiveness to improve outcomes.
Area of Science:
- Veterinary Oncology
- Surgical Pathology
Background:
- Soft tissue sarcomas (STS) originate from mesenchymal tissues in dogs.
- Local recurrence and metastatic disease (40% of high-grade tumors) are significant challenges.
- Current understanding of STS biology and optimal management remains incomplete.
Purpose of the Study:
- To provide an updated review on the management of canine soft tissue sarcomas.
- To address uncertainties in predicting optimal surgical margins.
- To discuss the impact of tumor aggressiveness on treatment strategies.
Main Methods:
- Literature review of current scientific evidence.
- Analysis of factors influencing treatment outcomes.
- Discussion of diagnostic and prognostic indicators.
Main Results:
- No reliable diagnostic tests exist to predict required surgical margins.
- Historical recommendations for wide excision margins are not consistently supported by recent evidence.
- Treatment outcomes are influenced by tumor aggressiveness and surgical margin strategy.
Conclusions:
- Canine soft tissue sarcoma management requires a nuanced approach.
- Tailoring surgical margins based on tumor characteristics is crucial.
- Further research is needed to refine diagnostic and prognostic tools for optimal clinical management.
